CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicThe Role of Immunotherapy in Cancer Therapy and Its ChallengesView all 16 articles
Polatuzumab Vedotin-R-CHP used for High-Risk EBV-Negative DLBCL-Type Post-Transplant Lymphoproliferative Disorder in a Long-Term Kidney Transplant Recipient:A Case Report
Provisionally accepted
Xiaoyu Jiang1Chunping Wu1Yuxun Oswald Zhang2Mingqing Luo1Yiwen Qiu1Miao Li1Lianshan Zhan1
Daping Zhong1*- 1Guiqian International General Hospital (GIGH), Guiyang, China
- 2Kyoto Daigaku, Kyoto, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This case describes the occurrence of high-risk EBV-negative DLBCL-type PTLD in a kidney transplant recipient with a 23-year graft history. For PTLD after solid organ transplantation, the standard initial approach is reduction in immunosuppression therapy, with rituximab monotherapy or R-CHOP chemotherapy. A recently introduced regimen, Pola–R–CHP, achieved a favorable initial response and contributed to disease stabilization in this patient. However, the subsequent central nervous system relapse implies the ongoing need for CNS prophylaxis, which should be carefully considered within the context of overall risk.
Keywords: Diffuse large B-cell lymphoma, Immunosuppression, Polatuzumab vedotin, Post-transplant lymphoproliferative disorder, prognostic factors, targeted therapy
Received: 26 Jul 2025; Accepted: 09 Dec 2025.
Copyright: © 2025 Jiang, Wu, Zhang, Luo, Qiu, Li, Zhan and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Daping Zhong
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.